- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04158037
Don't Go There: A Geospatial mHealth App for Gambling Disorder
August 20, 2025 updated by: Jeremiah Weinstock, St. Louis University
The goal of this project is to develop and to test the efficacy of a novel mHealth app for gambling disorder.
The app capitalizes on smartphones' global positioning software (GPS) that recognizes a user's location to within 15 feet.
Users will receive an alert of this go near a gambling venue.
The project will conduct a 12-week pilot randomized clinical trial to test the short-term efficacy of the app with gambling disorder individuals.
Study Overview
Study Type
Interventional
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Missouri
-
St Louis, Missouri, United States, 63108
- Saint Louis University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Currently meets DSM-5 criteria for gambling disorder
- At least 4 non-online gambling episodes in past 60 days
- Wagering at least $100 total over past 60 days
- Willingness to accept random assignment
- English speaking
- Android phone user
Exclusion Criteria:
- Age <18 years old
- Severely disruptive behavior
- Serious uncontrolled psychiatric behavior that requires acute psychiatric care
- Decline permission to collect zero permission data from smartphone.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: mHealth App
Participants will receive the gambling disorder mHealth app.
|
The app uses smartphones' global positioning software (GPS) that recognizes a user's location to within 15 feet.
The app will construct a customizable geofence (e.g., 3 miles) around a gambler's favored gambling venue (e.g., casino, gas station).
If the individual crosses the fence boundary his or her phone will raise the alarm with a personalized motivational message.
|
|
No Intervention: Wait List Control
Participant will be placed on a wait list for 12 weeks, after which they will be offered the gambling disorder mHealth app.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
App usage (feasibility)
Time Frame: From baseline to post-treatment (12 weeks)
|
Number of days the app is active on a user's smartphone.
Days can range from 0 to 84.
|
From baseline to post-treatment (12 weeks)
|
|
Patient satisfaction with the gambling app
Time Frame: From baseline to post-treatment (12 weeks)
|
Investigator derived patient satisfaction self-report questionnaire.
Five items, using a 7-point Likert scale from very dissatisfied (1) to very satisfied (7).
Higher scores indicate a better outcome.
|
From baseline to post-treatment (12 weeks)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Gambling behavior via Timeline Followback (Weinstock, Whelan, & Meyers, 2004)
Time Frame: From baseline to post-treatment (12 weeks)
|
Self-report gambling frequency and intensity as assessed by the Gambling Timeline Followback - a retrospective self-report calendar.
Gambling frequency can range from 0 to 84; gambling intensity is measured in $ and time (hours).
Dollars wagered can range from $0 to unlimited $.
Time is measured in hours and can range from 0 to >1,000 hours.
Higher scores indicate a worse outcome.
|
From baseline to post-treatment (12 weeks)
|
|
Gambling-related harms (Browne et al., 2018)
Time Frame: From baseline to post-treatment (12 weeks)
|
Self-reported gambling harms as assessed by the 72-item Gambling-Related Harms Questionnaire (yes/no responses).
Scores range from 0 to 72.
Higher scores indicate a worse outcome.
|
From baseline to post-treatment (12 weeks)
|
|
Quality of Life Inventory (Frisch et al., 1994). A self-reported quality of life measure assessing 17 domains of life for importance and satisfaction.
Time Frame: From baseline to post-treatment (12 weeks)
|
Self-report quality of life questionnaire.
Participants rate 17 domains on importance (range not at all important [0] to extremely important [2]).
The 17 domains are then rated on how satisfied the individual is regards to his or her life (-3 [very dissatisfied] to 3 [very dissatisfied]).
A total score is then generated by summing the product of importance multiplied by satisfaction.
Scores range from 0 to 102.
Higher scores indicate a better outcome.
|
From baseline to post-treatment (12 weeks)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Jeremiah Weinstock, PhD, St. Louis University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 31, 2024
Primary Completion (Actual)
May 31, 2025
Study Completion (Actual)
June 1, 2025
Study Registration Dates
First Submitted
November 5, 2019
First Submitted That Met QC Criteria
November 7, 2019
First Posted (Actual)
November 8, 2019
Study Record Updates
Last Update Posted (Estimated)
August 27, 2025
Last Update Submitted That Met QC Criteria
August 20, 2025
Last Verified
August 1, 2025
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 30494
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gambling Disorder
-
University of Nevada, Las VegasNot yet recruitingGambling Disorder | Pathological Gambling | Problem Gambling | Behavioral AddictionUnited States
-
Université Catholique de LouvainCentre Hospitalier Universitaire Vaudois; Cliniques universitaires Saint-Luc-... and other collaboratorsUnknownCraving | Gambling | Gambling Disorder | Gambling, Pathological | Gambling ProblemSwitzerland
-
ITAB - Institute for Advanced Biomedical TechnologiesNot yet recruitingAccelerated rTMS in Gambling Disorder: a Multicentric, Randomized, Sham-controlled Trial (arTMSinGD)Gambling | Gambling Disorder | Gambling, Pathological | Gambling Problem
-
Karolinska InstitutetCompleted
-
East Tennessee State UniversityNot yet recruitingGambling Disorder | Gambling ProblemUnited States
-
Region SkaneLund UniversityRecruitingGambling Disorder | Problem GamblingSweden
-
Universitat Jaume INot yet recruitingGambling Disorder | Problem GamblingSpain
-
University of ChicagoCompleted
-
Nantes University HospitalNot yet recruitingPsilocybin AsSisted pSychotherapy for the treatmENt of Gambling disordER : a Pilot Study (PASSENGER)Gambling DisorderFrance
-
Stanford UniversityKindbridge Research InstituteNot yet recruitingGambling Disorder | Gambling Problem | Mental Health Issue
Clinical Trials on mHealth App
-
Fatima Jinnah Women UniversityNot yet recruitingType 2 Diabetes Risk Reduction in Young AdultsPakistan
-
Tulane UniversityOsaka University; Centre Suisse de Recherches Scientifiques en Cote d'Ivoire; Institut Pasteur of Cote d'Ivoire and other collaboratorsRecruiting
-
Hospital Universitari de BellvitgeVifor PharmaActive, not recruiting
-
University of NicosiaCompletedTelemedicine | Pressure Ulcer | CaregiversCyprus
-
Washington University School of MedicineWashington University Institute of Clinical and Translational SciencesCompletedAnxiety Disorders | Adolescent DepressionUnited States
-
University of Missouri-ColumbiaCompletedOverweight AdolescentsUnited States
-
Ohio State UniversityWashington University School of Medicine; University of Illinois at Chicago; Vanderbilt...RecruitingSickle Cell DiseaseUnited States
-
University of California, DavisCompletedPsychosis | Clinical High Risk for PsychosisUnited States
-
The University of Texas Health Science Center,...Eunice Kennedy Shriver National Institute of Child Health and Human Development...Not yet recruitingAutism Spectrum Disorder (ASD)United States
-
Medical University of South CarolinaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingMedication Adherence | Medication ComplianceUnited States